Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL... Good one...
For Cannabis Industry Investment, 2018 Was Terrific But 2019 Looks Even Better
Today 10:34 AM ET (Benzinga)Print
It may be taken as a given that in the recent past speculators and stakeholders alike have watched a veritable comet’s arc in collective investment amid the cannabis space. An industry worth $910 million in 2015 reached $13.8 billion in 2018, and it seems bound only sunward yet: The bottom line is, the sky’s the limit.
The market has vast potential for generating future profits. It has not yet been six months since Canada activated its nationwide adult-use program, though the industry has meanwhile grown massively, welcoming companies and investment from quarters previously thought unimaginable to have any involvement.
For now, the leading quartet of companies – Canopy Growth Co (NYSE: CGC), Aurora Cannabis Inc (NYSE: ACB), Tilray Inc (NASDAQ: TLRY), and Cronos Group Inc (NASDAQ: CRON)– which are exclusively involved with cannabis seem likely to reach newer heights of valuation even as they combine to lose vast amounts on an operating basis. Even if not simultaneously so, each of those popular, brand-name cannabis stocks seem poised to turn inexorably toward profitability.
The Cannabis Capital Conference returns to Toronto April 17-18!
Given its capacity for a reported 700,000 kilos (1.54 million lbs.) in peak annual output, Aurora Cannabis represents Canada’s largest producer, a position which makes it seem likeliest to be first in becoming profitable on an operating basis (i.e., without aid from one-time benefits or fair-value adjustments).
With friends like Altria (and its $1.8 billion equity investment), Cronos may also cruise toward profitability if for other reasons. Whereas Aurora has more than a dozen production facilities to operate, Cronos’ profiteering agility stems from its advantage of running but two major production facilities (its joint venture Cronos GrowCo and Peace Naturals) and keeping costs down while it implements its margin expansion through sales of alternative cannabis products.
Tilray was the first cannabis company to make an initial public offering on the NASDAQ, and it has been capitalizing on lucrative opportunities through partnerships with companies like Anheuser-Busch InBev (NYSE: BUD) and Novartis AG (NYSE: NVS). But earlier this month Tilray’s CEO commanded headlines by alluding to an oversupply situation soon coming to Canada, and asserting that Tilray’s long-term strategy is more about the European and U.S. medical marijuana markets than in Canada’s much smaller respective market size.
Meantime, most of the overall market growth this year will expectedly derive from Canada’s settling in with its adult-use sales, while in the U.S. folks will impatiently abide California’s muddling through its early missteps in establishing its own adult-use market and supply chain.
Some on Wall Street have thrown some shade that Canopy will not turn a profit until 2021, but by any other measure it is clearly enjoying a rosy view: Being the second-largest producer – with a reported peak annual output of 500,000 kilos (1.1 million lbs.) sitting atop a summit of cash totaling more than $4 billion handed them by Constellation Brands, Inc.(NYSE: STZ) has a way of brightening one’s outlook. Meanwhile it will be restless to deploy some of that capital to efficiently corner some of the Canadian market share, prepare a blitzkrieg on both the American beverage space and hemp market, and to expand overseas as programs come online for more export opportunities.
Obviously, the recent rise of the legal cannabis industry has been nothing short of remarkable, and the momentum enjoyed in 2018 has lent impetus to what has so far been seen in 2019. Yet, as individual states’ respective interests lead the United States federal government further toward the tipping point for nationwide legalization, and more global jurisdictions look to eliminate prohibition throughout the world, those aforementioned blue skies are looking ever closer within investors’ reach.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
I would hold some thru this transaction period just in case. Many years of gold operations must be worth a big payday at some point.
BioCann and Instadose.... The first hemp Bio fuel company in the world in the making?
100,000 hectares of hemp is a ton.. I wouldn't be surprised if Instadose/Biocann will be involved with making a biofuels with hemp. Maybe these guys are the beginning of something much bigger than just CBD oil down the road.... BioCann= Hemp Biofuels someday? You never know.
Well Said. It's like the gym gives you Zen powers or something. Totally agree.
She's Been holding well at 15's for many days.. Seems to be the bottom. To much potential in the CBD game right now. Seems many now know of POTN's buyout target potential. Even if it isn't bought out the company can became massive on it's own.
Aurora Cannabis
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), one of the world's largest and leading cannabis companies, recently provided an update on its strategic investment in Choom Holdings Inc. (CSE: CHOO)--an emerging consumer cannabis company that has secured one of the largest retail networks in Canada.
Since Aurora's $27 million investments in Choom (which included a private placement in June 2018 and a convertible debenture offering in November 2018), Choom has secured 22 additional cannabis retail opportunities in Alberta and British Columbia. And with the acquisition of Clarity Cannabis Retail Stores, Choom has gained another 30 potential retail locations across Alberta--3 of which have already been licensed by the Alberta Gaming, Liquor & Cannabis Commission (AGLC).
To date, Choom has completed the buildouts of 17 retail locations in Western Canada with 8 other retail locations currently under construction. Despite Choom's vast potential retail reach, Aurora notes that all of Choom's current retail opportunities are subject to provincial regulatory approvals.
I would like to think all these gold and silver mines will finally amount to something after all these years. That's a lot of mines.... And they probably accumulated a ton of gold and silver. GNCP shareholders I think are going to be rich possibly.
Whats this device already MAtt?
$$$$$$ACB$$$$$$$
http://www.marketwatch.com/story/aurora-cannabis-leads-sector-rally-on-news-its-hiring-hedge-fund-manager-nelson-peltz-as-adviser-2019-03-13
Gonna be outperforming our peers from here on out!
Seems of higher quality news that might get this trains engines started and on it's way chugging up to .10 like all these PR's about .10 cents be saying
Aurora Cannabis Inc ACB:NYSE
Aurora Cannabis' stock heads for 3rd-straight monthly gain to outperform its peer group
MarketWatch
10:28 AM ET
Shares of Aurora Cannabis Inc. (ACB.T) hiked up 1.1% in active morning trade Friday, putting them on track to outperform the broader cannabis sector by posting a third-straight monthly gain. The stock was up 18.0% in March, after rising 6.6% in February and 42.9% in January, for a year-to-date gain of 79.9%. Meanwhile, the ETFMG Alternative Harvest ETF (MJ) was up 0.3% Friday, but has lost 2.5% this month and gained 45.0% this year. In comparison, the S&P 500 has edged up 1.5% this month. Aurora's stock rally in March comes after the company said earlier in the month that it hired hedge-fund manager Nelson Peltz (http://www.marketwatch.com/story/aurora-cannabis-leads-sector-rally-on-news-its-hiring-hedge-fund-manager-nelson-peltz-as-adviser-2019-03-13) as an adviser and Cowen designated the company as its "top pick." (http://www.marketwatch.com/story/aurora-cannabis-leads-sector-after-stock-is-named-top-pick-at-cowen-2019-03-05) On Thursday, the U.S. House Financial S ervices Committee cleared the Secure and Fair Enforcement (SAFE) Banking Act (http://www.marketwatch.com/story/cannabis-banking-bill-easily-clears-house-financial-services-committee-2019-03-28), which would provide a safe harbor for banks working with the legal cannabis industry, to go to the House floor.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
You would have to be crazy to sell right now. The fins could be released today. Audited or not it will run at least a 3-5 cents minimum because I guarantee these guys are making fat cash.
cool thanks for the feedback i just might do that. The drinks and the packaging certainly look very impressive.
That sparkling blueberry apple rush sounds awesome right now. This stock fell hard. Is this a good entry point? Or did something crazy bad happen with this company?
Longs who accumulate get a cherry on top of their ACB sundae. Some People on here are straight up sallies lately.....
Info about Nelson Peltz. If this guy is involved with ACB....ACB is going to make some serious money...
Business career
In 1963, he dropped out of the University of Pennsylvania's Wharton School with the intention of becoming a ski instructor in Oregon.[13] However, he ended up driving a delivery truck for A. Peltz & Sons, a wholesale food distribution business founded by his grandfather Adolph in 1896, which delivered fresh produce and frozen food (Snow Top)[14] to restaurants in New York.[6][9]
His father gave him free rein with the company, and over the next 15 years he and his older brother, Robert B. Peltz, grew the business gradually shifting the product line from produce to institutional frozen foods.[15] Over the next 10 years, Peltz bought up several food companies, and in 1972, he and his brother took their company, then called Flagstaff Corp., with $150 million in sales, public.[9][13] In 1982 his brother Robert bought back the assets of Peltz Food from Flagstaff after it went bankrupt.[15]
In the 1980s, Peltz and his business partner, Peter May, who had joined Flagstaff as chief financial officer after having been its accountant, went looking for new acquisitions. In April 1983, the two bought a stake in vending-machine and wire company Triangle Industries Inc. with the idea of using it to make acquisitions, building it into a Fortune 100 industrial company.[16] Triangle was sold to Pechiney in 1988.[17]
In 1997, through an investment vehicle they controlled, Triarc Cos,[18] Peltz and May acquired Snapple, from Quaker Oats. Snapple, together with other beverage brands was sold to Cadbury Schweppes in 2000. The Snapple turnaround was featured as a Harvard Business School case study.[18]
In 2005, Peltz, May, and Ed Garden, founded Trian Fund Management, L.P. As an activist investing firm, Trian has invested in such companies as Heinz,[19] Cadbury, Kraft Foods,[20] Ingersoll Rand,[21] Wendy's,[22] DuPont,[23] Mondelez,[3] PepsiCo,[24] State Street Corporation [25] and Family Dollar.[26]
In 2006, Trian was involved in a proxy contest with Heinz to get five independent directors on the board of Heinz. Trian succeeded in getting two members on the board, including Peltz.[27]
In 2007, Trian bought a 3% share of Cadbury-Schweppes. Cadbury Schweppes Americas Beverages was later spun off from the Cadbury Schweppes confectionery group. In 2007, Trian also bought $1.8 billion in shares of Kraft Foods, roughly a 3% of the total equity of the food maker.[28]
In April 2008, it was announced that Triarc Cos. would merge with burger chain Wendy's.[29] The merger was completed on September 29, 2008.[30] The new company was named Wendy's Arby's Group and traded on the New York Stock Exchange under the symbol WEN. On July 25, 2011, Wendy's Arby's sold Arby's to Roark Capital Group and changed its name to The Wendy's Company.[31] According to CNBC, on February 15, 2011, Trian offered to buy Family Dollar for $55–60 per share.
In February 2011, Trian announced it had accumulated an 8% stake in the Family Dollar company and indicated a willingness to participate in a take private LBO for the company with a total value of about $7 to $8 billion. This overture was rejected by the company management and board of directors.[32] In September 2011, Ed Garden, Trian's Chief Investment Officer, joined the Family Dollar board.[33]
Peltz was appointed to the Ingersoll-Rand board of directors in 2012.[34]
In August 2013, it was reported that Trian held an approximate $1.25 billion stake in DuPont.[23]
In January 2014, as one of the company's largest shareholders, with a current beneficial ownership of more than 46 million shares, Peltz was appointed to the board of directors of global snacking company, Mondelez International (NASDAQ: MDLZ).[35][36]
In February 2014, as a beneficial owner of approximately $1.2 billion of PepsiCo, Inc. (NYSE: PEP) common shares, Trian publicly released a letter to PepsiCo's board of directors and a white paper detailing why separating global snacks and beverages into two independent public companies would be the right long-term decision for the business and would create substantial value for shareholders.[37] Trian said it would immediately begin to engage fellow shareholders in a public dialogue with the goal of creating a groundswell of support for a separation of snacks and beverages.[38]
In February 2014, Forbes listed Peltz as one of the 25 highest-earning hedge fund managers in 2013, with total earnings of $430 million, ranked 16th.[39]
In May 2015, Trian was unsuccessful in a bitter proxy contest to appoint four of its nominees to the board of DuPont.[40] Five months later the CEO of DuPont, Ellen Kullman, resigned; at the time DuPont acknowledged lower than expected earnings and the need to accelerate a cost-cutting plan.[41]
In October 2015, Trian bought a $2.5 billion stake in General Electric.[42]
In October 2017, Peltz tried but failed to acquire a seat on the board of Procter & Gamble, in which Trian has a 1.5% stake.[43] On November 15, 2017, it was discovered that per a revision of all votes, which Peltz acknowledged to have resulted in a remarkably close battle, Peltz had in fact won the proxy battle, recognized as the largest in corporate history. On December 15, Procter & Gamble named Peltz to its board, although it stated that Peltz had nominally lost the proxy vote.[44]
In February 2018, Peltz announced his departure from the board of Mondelez International, to be succeeded by Trian President Peter May.[45]
In March 2018, Peltz joined the Procter & Gamble board of directors.[46][47]
In March 2019, Peltz joined Canadian cannabis producer Aurora Cannabis as a strategic adviser.
Pre market might be amazing tomorrow.
That's a lot of products!!! EDMONTON, March 28, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the Company and its wholly-owned subsidiary CanniMed Therapeutics, have added product information numbers (PINs) to 78 medical cannabis products to better facilitate and track insurance coverage for their Canadian patients. The products that received PINs include dried flower, capsules, soft gels, topicals and oils.
PINs help employers and insurance companies classify and incorporate health care products into benefit coverage plans. Patients submitting claims to their third-party insurer can now identify specific products and thereby speed up the adjudication and medical coverage process. MedReleaf, another wholly-owned subsidiary of Aurora, introduced PINs to 57 medical cannabis products in 2018.
Wish I got in today instead of yesterday. Them delaying that vote till this morning was some pointless B.S. Should we expect a vote in the Senate today or tomorrow possibly?
LOL... That's for sure
The Bill easily passed on a bipartisan bill. 45-15.. I say Cannabis will have no problems the rest of the way. 2019 Federal Legalization is going to happen! When will Mitch the Bitch Mcconnell vote on the banking bill?
It sure is about to get interesting. 2019 is going to be amazing for Cannabis investors.
You came with that news before TD Ameritrade and IHUB. Good Job.
Does POTN have the name Diamond CBD and Diamond THC copyrighted? If so that only increases the odds they will be a huge buyout target. That is more what I am counting on. Someone like ACB or CGC buying POTN/ Diamond CBD
Biocann Instadose Gonna be doing business in the USA! https://www.forbes.com/sites/tomangell/2019/03/28/marijuana-banking-bill-approved-by-congressional-committee/amp/?__twitter_impression=true
Legalization is predicted to happen very soon. Vote in a few weeks!
Diamond THC is coming soon!
Good man Green Dragon! Did it pass yesterday or today.
Vote at 10 I was told.
When is the banking bill vote happening
Major Retailer Begins Sales of CBD Around the U.S. as the Market Continues to Develop
9:00 am ET March 28, 2019 (PR Newswire) Print
Decades ago cannabis was illegal in essentially every country, now, Canada and Uruguay are the leading countries who have moved to legalize cannabis entirely. A handful of other countries such as Australia, Columbia, Germany, and the U.S. are also major cannabis marketplaces, even though they have not legalized cannabis entirely yet. However, cannabis remains a Schedule 4 drug under the Single Convention on Narcotic Drugs, which is the strictest regulation. Nonetheless, the rapid emergence of cannabis has prompted many companies to seek entry into the industry, which is seeing investments pour in from various sectors such as alcohol, tobacco, and most recently, the pharmaceutical industry. CVS Health, a major international pharmaceutical chain, recently entered into the cannabis industry by offering hemp derived CBD-based products in its stores. Due to regulatory conflict, CVS announced that it will only sell the products in specific U.S. states such as Alabama, California, Colorado, Illinois, Indiana, Kentucky, Maryland and Tennessee across 800 stores. CVS also said that the chain is carrying CBD products now to help these select states meet consumer demand for alternative care options. CVS' initiative to add a cannabis derivative on its shelves is yet another major milestone for the industry, adding credibility to the benefits of cannabis by highlighting that its hemp derivative offers consumers therapeutic effects. As more sectors continue to enter into the cannabis marketplace, the industry will develop into a global, disruptive scene. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023. Furthermore, the market is projected to register a robust CAGR of 37% throughout the forecast period. CLS Holdings, USA Inc. (OTC: CLSH) (CSE: CLSH.U), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN), Intec Pharma Ltd. (NASDAQ: NTEC), AXIM Biotechnologies, Inc. (OTC: AXIM)
CVS' Chief Executive Officer Larry Merlo mentioned in an interview with CNBC that he's received feedback from many CBD consumers, saying that it has helped them manage medical conditions such as pain, arthritis, and other ailments. Furthermore, international agencies like the World Health Organization have conducted studies regarding cannabis and concluded that current research is sufficient enough to reevaluate the current international control of the plant. Last year, the World Health Organization Expert Committee on Drug Dependence (ECCD) met several times to discuss the matters of cannabis. The biggest takeaway is that the ECCD noted that pure cannabidiol or CBD can be effective in treating certain medical applications such as childhood epilepsy, which the U.S. Food and Drug Administration has already approved Epidiolex as a treatment. Additionally, the ECCD also mentioned that cannabis helped patients manage side effects of conditions such as HIV/AIDS, Parkinson's, dementia, and muscle spasms. However, the ECCD also highlighted that more research and studies are required in order to fully understand cannabis and its effects. As clinical trials continue to release positive results, cannabis can inch closer to becoming an approved and registered form of medicine in the future. "Medical marijuana is an early sign of the change in the view of cannabis," said Jordan Waldrep, Portfolio Manager at USA Mutuals Vice Fund, "The legalization of medical marijuana and cannabis-derived drugs represents a significant change in thinking for the societies that have chosen to allow its consumption by patients. Then, as patients see benefits and more research is done, the concerns on the potential for high abuse or severe safety concerns come into question as well, thus opening a path to recreational marijuana over time."
CLS Holdings, USA Inc. (OTCQB: CLSH) (CSE: CLSH.U) is also listed on the Canadian Securities Exchange under the ticker (CSE: CLSH.U). Earlier this month, the Company announced that, "it has entered into a definitive agreement to acquire an 80% ownership interest in CannAssist, LLC. This agreement, along with the previously announced option agreement to acquire In Good Health, marks a continuation towards CLS's goal to become a significant entity in the rapidly growing Massachusetts market.
CannAssist has entered into a contract with the City of Leicester and has applied for a state cultivation grow license. The planned Leicester 86,000 square foot facility is expected to produce its first harvest in Q1 of 2020. This facility is expected to produce 28000 pounds of flower along with 240,000 grams of extract. Once fully operational, total revenues from the facility are anticipated to exceed $100 million. CLS anticipates generating substantial positive cash flow from the grow facility.
Massachusetts has a population of 6.9 million people as compared to 5.6 million people in Colorado. Massachusetts is also centrally located to the dense population of New England with a less than 100-mile drive from Rhode Island, Connecticut, New York, New Hampshire and Vermont. The city of Denver currently has approximately 364 dispensaries compared with the entire State of Massachusetts, which currently has less than 50.
Jeff Binder, Chief Executive Officer of CLS Holdings USA, commented, 'We are extremely excited to enter into this agreement. The market dynamics in Massachusetts are compelling for large scale cultivation. The current cultivation in Mass is approximately 800k square feet, while demand is expected to exceed 8,000,000 square feet. This opportunity fits into our stated objective of entering markets that are on the cusp of implementing a robust adult use market'.
About CannAssist: CannAssist has entered into a contract with the city of Leicester and has applied for a state cultivation grow license. It plans to build a facility that upon completion will have 86000 square feet of cultivation space making it one of the top 3 facilities in the state. The company expects to begin operations and realize its first harvest in Q1 of 2020.
About Oasis Cannabis: Oasis Cannabis has operated a cannabis dispensary in the Las Vegas market since dispensaries first opened in Nevada in 2015 and has been recognized as one of the top marijuana retailers in the state. Its location within walking distance to the Las Vegas Strip and Downtown Las Vegas in combination with its delivery service to residents allows it to efficiently serve both locals and tourists in the Las Vegas area. In February 2019, it was named "Best Dispensary for Pot Pros" by Desert Companion Magazine.
In August 2017, the company commenced wholesale offerings of cannabis in Nevada with the launch of its City Trees brand of cannabis concentrates and cannabis-infused products. http://oasiscannabis.com
About CLS Holdings USA, Inc: CLS Holdings USA, Inc. (CLSH) is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada, and plans to expand to other states. CLS stands for "Cannabis Life Sciences," in recognition of the Company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The Company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services."
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 24 countries across five continents, is one of the world's largest and leading cannabis companies. Aurora Cannabis Inc. recently announced that it has commenced sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German monograph for in-pharmacy preparation. Aurora is the medical cannabis market leader in Germany. The Company has supplied the German market with dried cannabis flower via Aurora Deutschland (formerly Pedanios) since December 2015, and with Canadian-grown Aurora products since September 2017. Aurora has established a strong brand as a trusted supplier among prescribing physicians, dispensing pharmacies, and German patients. As one of the few companies able to sell oils in this rapidly growing market, Aurora is well positioned to establish brand leadership in the European derivatives market. "Having established early mover advantage in selling cannabis oils in Germany, we are exceptionally positioned to extend our market leadership and accelerate the growth of our European operations," said Neil Belot, Chief Global Business Development Officer. "As our global production capacity continues to ramp up, we are able to strategically allocate more product from our EU GMP certified cultivation facilities to this higher margin market that continues to be significantly undersupplied."
iAnthus Capital Holdings, Inc. (OTCQX: ITHUF) (CSE: IAN) owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. iAnthus Capital Holdings, Inc. recently announced that it has opened its second New York dispensary, located in the Dutchess County town of Wappingers Falls. The dispensary will operate as "Citiva Hudson Valley" under iAnthus' "Citiva" New York dispensary brand. The 2,600 sq. ft. dispensary is located at 1147 Route 9 in Wappingers Falls, a short drive from Beacon Train Station on the Metro-North Railroad, Marist College, Vassar College, and a collection of New York historical sites. The retail location initially will offer more than 30 locally-sourced, lab-tested products, including vape cartridges, tinctures, capsules, and powders, dispensed by highly-knowledgeable patient care representatives. "The opening of our Citiva Hudson Valley dispensary is a major milestone for iAnthus, as it marks the 20th dispensary opened by the Company," said Hadley Ford, Chief Executive Officer of iAnthus. "2019 will be full of catalysts and exciting developments for Citiva, including the much-anticipated completion of our cultivation facility in Warwick, New York, and the opening of dispensaries in Staten Island and Chemung County."
Intec Pharma Ltd. (NASDAQ: NTEC) is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Intec Pharma Ltd. recently announced the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill(TM) platform containing synthetic tetrahydrocannabinol (THC), one of the primary cannabinoids contained in cannabis. The Phase 1 PK study is a single-center, single-dose, randomized, open-label three-way crossover study to investigate the PK, safety and tolerability of AP-THC in up to 18 normal healthy volunteers. "We are very pleased to be advancing our medical cannabinoid development program as we believe the Accordion Pill's gastric retentive technology is ideally suited to extend the absorption phase of THC, with the goal of a slower rate of rise and more consistent drug plasma levels after oral delivery. The combination of the slower rate of rise with sustained and consistent plasma levels is expected to lead to an improved therapeutic effect and reduce the adverse events that are correlated with rate of rise and peak THC plasma levels," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. AXIM Biotechnologies, Inc. recently announced the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) on a method to treat atopic dermatitis, also known as eczema, using a topical cream containing cannabinoids - specifically cannabidiol ("CBD") and cannabigerol ("CBG"). The USPTO granted this allowance from AXIM's patent application 16/106,524, filed on August 21, 2018. With this patent allowance, AXIM has formulated a topical cream for relief of itching, pain and inflammation that often accompany atopic dermatitis. All creams formulated under this patent will contain cannabinoids and utilize AXIM's proprietary combination of CBG and CBD. AXIM's topical cream is projected to be one of the first CBG products available on the market. "As AXIM moves forward with its long-term business strategy, this patent allowance offers the opportunity to bring another one of our innovative products into the pipeline for both pharmaceutical and nutraceutical markets," said John W. Huemoeller, Chief Executive Officer of AXIM Biotech. "This patent allowance expands our intellectual property portfolio and makes room for us to build treatment options for consumers suffering from varying medical conditions. Through the formulation of one of the first CBG products available to consumers, AXIM remains a leader in cannabinoid research and development."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com